Here's a tip: don't fix cost price, and it looks like MRG only sucks a little bit in your portfolio, rather than dismal failure it really is.
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress